Table 1.
Demographics, Task Performance, and Clinical Characteristics of Participants
| +CBTp Group (n = 22, 18 Male) | SCO Group (n = 16, 14 Male) | Healthy Participants (n = 20, 15 Male) | ||||||
|---|---|---|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | Mean (SD) | ||||||
| Baseline | Follow-up | Baseline | Follow-up | Baseline | ||||
| Age (years) | 35.7 (7.82) | 39.2 (9.37) | 37.3 (12.5) | |||||
| Education (years) | 13.9 (3.26) | 13.6 (1.71) | 14.8 (3.0) | |||||
| Predicted IQa | 109.4 (9.68) | 106.6 (9.73) | 115 (8.0) | |||||
| Age at illness onset | 24.8 (8.38) | 25.8 (8.49) | ||||||
| Duration of illness (years) | 10.9 (7.70) | 13.4 (10.2) | ||||||
| Medication | Atypical antipsychotic (n = 20); combined atypical and typical (n = 2) | Atypical antipsychotic (n = 14); combined atypical and typical (n = 2) | ||||||
| Chlorpromazine equivalent (mg) | 543 (479.3) | 448.9 (338.8) | ||||||
| Gender Discrimination Accuracy (%) | Neutral | 92.6 (10.8) | 91.8 (13.1) | 88.3 (10.8) | 90.0 (14.6) | 92.5 (18.3) | ||
| Fear | 90.5 (14.4) | 91.4 (16.5) | 87.9 (20.9) | 87.9 (18.5) | 92.7 (15.8) | |||
| Anger | 88.6 (15.2) | 88.9 (14.2) | 84.8 (16.1) | 87.3 (19.1) | 91.3 (19.4) | |||
| Happy | 94.7 (8.48) | 93.3 (9.94) | 92.4 (7.82) | 90.8 (12.3) | 94.5 (18.7) | |||
| Detection (%) | No face | 93.4 (12.4) | 91.5 (16.4) | 93.8 (13.7) | 92.5 (18.1) | 93.8 (22.3) | ||
| PANSSb symptoms | ||||||||
| Positive symptoms | 18.1 (4.84) | 14.9 (4.10) | t(21) = 3.90* | 18.6 (3.20) | 18.1 (3.30)ns | |||
| Negative symptoms | 17.7 (4.23) | 15.6 (4.29) | t(21) = 2.61* | 19.1 (4.13) | 20.3 (4.38)ns | |||
| General Psychopathology | 33.5 (7.24) | 28.6 (7.40) | t(21) = 2.97* | 35.4 (4.41) | 35.4 (6.49)ns | |||
| Total symptoms | 69.3 (13.3) | 59.0 (14.7) | t(21) = 3.72* | 73.1 (9.28) | 73.8 (11.8)ns | |||
| BDIc symptoms | 16.2 (8.3)d | 11.5 (9.9)*d | t(19) = 2.19* | 15.9 (10.4) | 15.8 (12.1)ns | |||
aNational Adult Reading Test.32
bPositive and Negative Syndrome Scale.33
cBeck Depression Inventory.34
dMissing data for 1 participant.
*Significant symptom reduction (P < 0.05) at follow-up relative to baseline.